SCHEMBL5836337

SCHEMBL5836337

COc1ccc(Oc2ccc(C(N)=O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 12/20 1.00
CA1 P00915 4/20 0.88
CA2 P00918 4/20 0.88
PARP2 Q9UGN5 3/20 0.88
PARP4 Q9UKK3 2/20 0.88
PARP1 P09874 1/20 0.88
PARP15 Q460N3 4/20 0.79
PARP14 Q460N5 2/20 0.79
ALDH1A1 P00352 1/20 0.79
KMT2A Q03164 1/20 0.79
PARP16 Q8N5Y8 1/20 0.79
PARP11 Q9NR21 1/20 0.79
PARP3 Q9Y6F1 1/20 0.61
MAP4K4 O95819 1/20 0.60
TNKS O95271 1/20 0.59
TNKS2 Q9H2K2 1/20 0.59
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
PRSS1 P07477 1/20 0.55
PRSS2 P07478 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201761 0.94 PARP10 (1.00) PARP10CA1CA2PARP2PARP4
Hydrochloric Acid SCHEMBL408766 0.91 PARP10 (0.95) PARP10CA1CA2PARP2PARP4
Hydrochloric Acid SCHEMBL4376056 0.91 PARP10 (0.95) PARP10CA1CA2PARP2PARP4
SCHEMBL3137816 0.89 PARP10 (1.00) PARP10CA1CA2PARP2PARP4
SCHEMBL27571315 0.88 PARP10 (0.88) PARP10CA1CA2PARP2PARP4
SCHEMBL7442028 0.88 PARP10 (0.88) PARP10CA1CA2PARP2PARP4
Acetic Acid SCHEMBL28396208 0.88 PARP10 (0.88) PARP10CA1CA2PARP2PARP4
SCHEMBL6167256 0.87 PARP10 (0.84) PARP10CA1CA2PARP2PARP4
SCHEMBL8406724 0.86 PARP10 (0.84) PARP10CA1CA2PARP2PARP4
SCHEMBL11600003 0.86 PARP10 (0.84) PARP10CA1CA2PARP2PARP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119201-B2 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC (US) 2006-10-10 US disclosed
EP-1501515-B1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 EP disclosed
EP-1501515-A1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-02 EP disclosed
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER PRODUCTS INC. 2004-01-08 US disclosed
WO-2003090752-A1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 PARP10 1850/4885CA1 1659/4885CA2 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.